← Back to Treatments
🏅 FDA Orphan Designation

Ztalmy

ganaxolone

Manufacturer: Marinus Pharmaceuticals

Indicated for:
CDKL5-deficiency disorderOrphan

FDA-Approved Indications (1)

CDKL5-deficiency disorderOrphan Designation

Treatment of seizures associated with CDKL5-deficiency disorder (CDD) in patients 2 years of age and older. Ganaxolone is a neuroactive steroid GABAA receptor modulator.

Indications & Usage

1 INDICATIONS AND USAGE ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ( 1 )

💙 Support Programs

View all →
Ztalmy
Marinus Pharmaceuticals

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.